Advantages
- First-in-class mechanism: Only known PPP1R3G/PP1γ inhibitor—differentiated from all RIPK1/RIPK3 competitors
- Upstream targeting: Acts before RIPK1 activation for potentially improved selectivity
- Validated efficacy: Demonstrated reduction in necroptosis markers (p-RIP1, p-RIP3, p-MLKL)
- Large unmet need: No approved DGF prevention therapy despite 95,000+ annual transplants
- Multiple indications: Platform potential beyond transplant
Summary
Delayed graft function (DGF) affects 25-30% of kidney transplant recipients, requiring dialysis in the first week post-surgery. Current immunosuppressive therapies don't address the underlying cell death mechanism—necroptosis—that drives graft injury. No FDA-approved therapy specifically prevents DGF.
Our researchers developed PGB-1, a novel peptidomimetic that specifically inhibits the PPP1R3G/PP1γ protein interaction—an upstream regulator of necroptosis. Unlike existing RIPK1 inhibitors, this targeted approach reduces cell death in kidney proximal tubular cells while minimizing off-target effects.
Desired Partnerships
- License
- Sponsored Research
- Co-Development